Lava Therapeutics Nv Stock Today
| LVTX Stock | USD 1.61 0.01 0.63% |
Performance0 of 100
| Odds Of DistressOver 56
|
LAVA Therapeutics is trading at 1.61 as of the 26th of November 2024; that is 0.63 percent up since the beginning of the trading day. The stock's open price was 1.6. LAVA Therapeutics has over 56 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for LAVA Therapeutics NV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of March 2021 | Category Healthcare | Classification Health Care |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. Lava Therapeutics is traded on NASDAQ Exchange in the United States. The company has 26.3 M outstanding shares of which 19.11 K shares are now shorted by private and institutional investors with about 0.34 trading days to cover. More on LAVA Therapeutics NV
Moving against LAVA Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
LAVA Stock Highlights
| President CEO | MSc MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLAVA Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand LAVA Therapeutics' financial leverage. It provides some insight into what part of LAVA Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LAVA Therapeutics NV (LVTX) is traded on NASDAQ Exchange in USA. It is located in Yalelaan 62, Utrecht, Netherlands, 3584 CM and employs 37 people. LAVA Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.34 M. LAVA Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 26.3 M outstanding shares of which 19.11 K shares are now shorted by private and institutional investors with about 0.34 trading days to cover.
LAVA Therapeutics NV currently holds about 110.71 M in cash with (38.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check LAVA Therapeutics Probability Of Bankruptcy
Ownership AllocationLAVA Therapeutics maintains a total of 26.3 Million outstanding shares. LAVA Therapeutics holds noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check LAVA Ownership Details
LAVA Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Walleye Trading Advisors, Llc | 2024-06-30 | 25.7 K | |
| Citadel Advisors Llc | 2024-09-30 | 17 K | |
| Engineers Gate Manager Lp | 2024-09-30 | 11.9 K | |
| Geode Capital Management, Llc | 2024-09-30 | 11.1 K | |
| Atlantic Trust Group, Llc | 2024-06-30 | 6 K | |
| Tsfg, Llc | 2024-09-30 | 400 | |
| Bank Of America Corp | 2024-06-30 | 400 | |
| Simplex Trading, Llc | 2024-06-30 | 226 | |
| Schonfeld Strategic Advisors Llc | 2024-06-30 | 0.0 | |
| Redmile Group, Llc | 2024-09-30 | 2.1 M | |
| Bruce & Co Inc | 2024-09-30 | 771.9 K |
LAVA Therapeutics Historical Income Statement
LAVA Stock Against Markets
LAVA Therapeutics Corporate Management
| Wouter Hunnik | VP Resources | Profile | |
| Hans MD | Chief Officer | Profile | |
| MD MBChB | Chief Officer | Profile | |
| Ton Adang | Chief Officer | Profile | |
| Peter Ros | VP Fin | Profile | |
| Paul Parren | Head VP | Profile |
Additional Tools for LAVA Stock Analysis
When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.